The technique could be commercialized and used to understand immune response to viruses and cancer in order to develop immunotherapies.
The company is using its MIRA assay internally and in research collaborations to identify biomarkers that can serve as the basis for immunotherapies.
Researchers used viral repertoire sequencing to characterize an early-stage HIV-neutralizing antibody, an important step toward developing a vaccine.
After scrapping initial plans to develop a diagnostic instrument, the company has been working for several years to advance its single-cell droplet platform for targeted drug development.
An NGS-based assay was better at diagnosing CTCL than PCR-based tests, and could distinguish between malignant and benign skin lesions and identify recurrence.
The technique can help provide a better understanding of transplant tolerance and may have implications for monitoring and predicting rejection.
Immune sequencing will be done in HudsonAlpha's newly established CLIA laboratory.
Adaptive hopes to develop a gold standard for immune sequencing using the combined technologies.
Adaptive Biotechnologies CEO Chad Robins will remain as CEO, and Sequenta CEO Tom Willis and CSO Malek Faham will join the senior leadership team.
Researchers are demonstrating that sequencing the immune repertoire can offer valuable insight into blood cancers, treatment response, and the likelihood of relapse.
A new report offers ways for small, society publishers to transition to Plan S standards, ScienceInsider says.
A gas explosion sparked a fire at a Russian laboratory that stores dangerous pathogens, the Guardian reports.
Researchers turn to protein analysis to examine an ancient rhino sample, Smithsonian.com reports.
In PNAS this week: C2CD4A gene involved in insulin secretion, chromosome rearrangements in recurring S. aureus infections, and more.